These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15833066)

  • 21. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
    Susser S; Flinders M; Reesink HW; Zeuzem S; Lawyer G; Ghys A; Van Eygen V; Witek J; De Meyer S; Sarrazin C
    Antimicrob Agents Chemother; 2015 May; 59(5):2746-55. PubMed ID: 25712364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New developments in the discovery of agents to treat hepatitis C.
    Rönn R; Sandström A
    Curr Top Med Chem; 2008; 8(7):533-62. PubMed ID: 18473882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapeutic potential of NS3 protease inhibitors in HCV infection.
    Goudreau N; Llinàs-Brunet M
    Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral determinants of resistance to treatment in patients with hepatitis C.
    Wohnsland A; Hofmann WP; Sarrazin C
    Clin Microbiol Rev; 2007 Jan; 20(1):23-38. PubMed ID: 17223621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals.
    Guardigni V; Cento V; Ianniruberto S; Badia L; Aragri M; Conti M; Perno CF; Viale P; Ceccherini-Silberstein F; Verucchi G
    Infection; 2018 Oct; 46(5):717-720. PubMed ID: 29804205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotype 3 Infection: The Last Stand of Hepatitis C Virus.
    Chan A; Patel K; Naggie S
    Drugs; 2017 Feb; 77(2):131-144. PubMed ID: 28074358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising Anti-Hepatitis C Virus Compounds from Natural Resources.
    Wahyuni TS; Utsubo CA; Hotta H
    Nat Prod Commun; 2016 Aug; 11(8):1193-1200. PubMed ID: 30725589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus infection: Are there still specific problems with genotype 3?
    Gondeau C; Pageaux GP; Larrey D
    World J Gastroenterol; 2015 Nov; 21(42):12101-13. PubMed ID: 26576095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.
    Soriano V; Labarga P; Vispo E; Fernández-Montero JV; Barreiro P
    Infect Dis Clin North Am; 2012 Dec; 26(4):931-48. PubMed ID: 23083825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct-acting and host-targeting HCV inhibitors: current and future directions.
    Chatel-Chaix L; Germain MA; Götte M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.
    Pietschmann T
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
    Papasavvas E; Azzoni L; Yin X; Liu Q; Joseph J; Mackiewicz A; Ross B; Lynn KM; Jacobson JM; Mounzer K; Kostman JR; Montaner LJ
    J Viral Hepat; 2017 Oct; 24(10):865-876. PubMed ID: 28419653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approaches for the development of antiviral compounds: the case of hepatitis C virus.
    Schinazi RF; Coats SJ; Bassit LC; Lennerstrand J; Nettles JH; Hurwitz SJ
    Handb Exp Pharmacol; 2009; (189):25-51. PubMed ID: 19048196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.